non-contact, real-time vessel blood flow speeds
Next raise on StartEngine.com
Expected in 2022
Vision & Robotics Engineering
Patents + Trade Secret
Robotics and computer vision engineers and clinicians tested the latest medical robot arm and imaging head unit in an engineering design facility. VU-FLOW R aims to provide surgeons with cobot mode (arm follows finger tip contact) and automation mode for quick targeting & parking between imaging runs.
Point-n-Shoot to Know-the-Flow
VU-FLOW imaging system is a mobile laboratory measurement instrument of fluid flow. It operates 200 mm (8 in) from the subject. It can measure flow as fast as 50 cm/seconds.
Intuitive and Informative
Easily visualize flow speeds along a surface (left) and flow speeds over time within the circle (right). The circle can be placed anywhere on the color flow map to explore speeds.
According to Inkwood’s Global Report, the blood flow measurement market is $500M in annual sales revenue. According to the World Health Organization (WHO), there are 312 million major procedures per year.
Blood flow sustains all tissue and organs by providing critical oxygen and nutrients and removing toxic byproducts.
Scinovia aims to displace 60-year-old legacy methods of chemical fluorescence injections and ultrasound probes with a non-contact, quantitative tool. Scinovia plans to acquire increasing levels of regulatory clearance as it accumulates and presents supporting data.
Assessing the blood flow for surgery is challenging and costly
Know-the-flow in real-time with VU-FLOW
Pay-per-use: With a fixed cost of $1k per use and the expected number of cases at 20/month (240/year), we would be making $240K/year, which is comparable to current contact devices.
3-year subscription option: We will offer a discounted subscription of unlimited use, e.g., $370K. Scinovia will sell this subscription to K2 Capital and/or Dext Capital for 81% to receive $300K cash up front. Scinovia will use this to front mfg, sales, and service and retain approximately 50% or $150K/subscription.
Expecting Revenue in 2021
$4M and 7 years of R&D produced our technological advantage.